Cargando…
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
BACKGROUND: Reversion mutations of somatic BRCA mutations are an important source of resistance within ovarian cancer. Furthermore, these reversion mutations are known to change over the course of treatment. Better understanding of the mechanisms leading to reversion mutations and the role of serial...
Autores principales: | Jacob, Saya L., Kiedrowski, Lesli A., Chae, Young K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218016/ https://www.ncbi.nlm.nih.gov/pubmed/32420470 http://dx.doi.org/10.1016/j.heliyon.2020.e03841 |
Ejemplares similares
-
Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in
BRCA1
and
BRCA2
genes among breast cancer patients in Tanzania
por: Rweyemamu, Linus P., et al.
Publicado: (2022) -
Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021) -
An integrated Asian human SNV and indel benchmark established using multiple sequencing methods
por: Huang, Chuanfeng, et al.
Publicado: (2020) -
SNV/indel hypermutator phenotype in biallelic RAD51C variant - Fanconi anemia
por: Zemet, Roni, et al.
Publicado: (2023) -
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)